INTEGRATED BIOPHARMA, INC. (INBP) Gross margin 2018–2026
INTEGRATED BIOPHARMA, INC. (INBP) gross margin by fiscal year — reported gross profit divided by reported revenue.
1.8%FY2026 · since FY2018: 11.4% → 1.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | 1.8% | -8.4 pp |
| FY2025 | 10.2% | +2.5 pp |
| FY2024 | 7.7% | -0.3 pp |
| FY2023 | 8.0% | -3.6 pp |
| FY2022 | 11.6% | -3.3 pp |
| FY2021 | 14.9% | +2.2 pp |
| FY2020 | 12.7% | +0.3 pp |
| FY2019 | 12.4% | +1.0 pp |
| FY2018 | 11.4% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More INBP financial trends
INBP RevenueINBP Net incomeINBP Net marginINBP Gross profitINBP Operating incomeINBP Operating marginINBP Operating cash flowINBP Free cash flowINBP Capital expendituresINBP Return on equityINBP Stock buybacksINBP Dividends paidINBP Total assetsINBP Total liabilitiesINBP Shareholders’ equityINBP overview →